NCT07712770|Not Yet RecruitingEarly Phase 1DMC
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
PRECISE
Loading search results
Sponsor study identifier
interventional
12
1 country
1
Study Start
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
November 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is testing a new way of treating brain tumours using tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres). These microspheres are placed into the blood vessels that feed the tumour. The treatment gives off radiation inside the tumour to try to stop it from growing. This type of treatment is called Selective Internal Radiation Therapy (SIRT), Transarterial Radioembolisation (TARE), or radioembolisation. It is already an accepted treatment for patients with liver cancer. In this study, we are testing if this treatment can be done safely in the brain and how well it works.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2, 2026
Actual (reported)July 17, 2026
Actual (reported)October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety - Treatment-related adverse events
Rate of any treatment-related adverse events within the first 30 days after TARE, according to CTCAE, version 6.0.
From SIR-sphere administration (Day 1) to 30 days post SIR-sphere administration.
Safety - Severe treatment-related adverse events
Rate of any severe treatment-related adverse events (grade ≥3-5) within the first 30 days after TARE, according to CTCAE version 6.0
From SIR-sphere administration (Day 1) to 30 days post SIR-sphere administration.
30-day mortality
Rate of all-cause mortality within 30 days following TARE.
From SIR-sphere administration (Day 1) to 30 days post SIR-sphere administration.
SIR-Spheres® will be administered intra-arterially by selective catheterisation of tumour-feeding arteries. The prescribed activity will be determined on an individual basis. The administered activity of SIR-Spheres® will be selected to achieve adequate coverage of the target, taking into account tumour burden within the treated volume, while keeping dose to normal brain within acceptable limits.
Single administration of SIR-Spheres® on Day 1 with optional one-time retreatment if clinically indicated
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Austin Hospital
Melbourne, Victoria, 3084, Australia
First Submitted
July 2, 2026
First Posted
July 17, 2026
Study Start
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
November 2028
EstimatedTechnical success of TARE
6 months after the last patient has been enrolled
Confirmation of dose delivery
6 months after the last patient has been enrolled.
Objective response rate (ORR)
6 months after the last patient has been enrolled
Disease control rate (DCR)
6 months after the last patient has been enrolled
Clinical and radiographic progression-free survival (PFS)
6 months after the last patient has been enrolled
To evaluate the correlation between organ at risk radiation dosimetry and adverse events
6 months after the last patient has been enrolled
To evaluate the concordance between pre-treatment predicted and post-treatment delivered absorbed dose distributions to tumour and normal brain using voxel-based dosimetry
6 months after the last patient has been enrolled
To investigate circulating biomarkers and potential mechanisms of resistance, for patients treated with this approach.
6 months after the last patient has been enrolled
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 17, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: